Skip to main content

Table 3 Univariate Cox regression analyses of systemic-recurrence-free survival and breast-cancer specific survival

From: Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome

BM samples

Parameter

Hazard ratio

95% CI

P-values

 

Systemic recurrence-free survival

   

BM1

DTC status (pos. vs. neg.)

5.944

2.713–13.022

<0.001

BM2*

DTC status (pos. vs. neg.)

5.013

2.133–11.782

<0.001

BM3*

DTC status (pos. vs. neg.)

3.680

1.062–12.744

0.040

BM2 and/or BM3

DTC status (pos. vs. neg.)

4.523

2.044–10.008

<0.001

BM1 and BM2/3

DTC status (pos. vs. neg.)

9.948

4.103–24.122

<0.001

 

Lymph node status (pN > 0 vs. pN0)

3.995

1.833–8.708

<0.001

 

Tumor size (pT3 and pT4 vs. pT2 vs. pT1)

1.523

0.691–3.358

0.297

 

Tumor grade (3 vs. 2 vs. 1)

2.015

1.212–3.352

0.007

 

Age (>55 or not)

1.044

0.484–2.252

0.913

 

ER (positive vs. negative)

0.322

0.143–0.723

0.006

 

PgR (positive vs. negative)

0.735

0.337–1.605

0.440

 

Adjuvant chemotherapy (received or not)

1.603

0.713–3.601

0.253

 

Adjuvant endocrine therapy (received or not)

1.814

0.832–3.951

0.134

 

Breast-cancer specific survival

   

BM1

DTC status (pos. vs. neg.)

5.408

2.271–12.880

<0.001

BM2*

DTC status (pos. vs. neg.)

3.880

1.470–10.238

0.006

BM3*

DTC status (pos. vs. neg.)

4.626

1.286–16.635

0.019

BM2 and/or BM3

DTC status (pos. vs. neg.)

3.851

1.592–9.316

0.003

BM1 and BM2/3

DTC status (pos. vs. neg.)

9.205

3.526–24.031

<0.001

 

Lymph node status (pN > 0 vs. pN0)

4.694

1.944–11.344

0.001

 

Tumor size (pT3 and pT4 vs. pT2 vs. pT1)

1.788

0.753–4.247

0.188

 

Tumor grade (3 vs. 2 vs. 1)

3.288

1.743–6.201

<0.001

 

Age (>55 or not)

1.384

0.583–3.284

0.461

 

ER (positive vs. negative)

0.217

0.091–0.516

0.001

 

PgR (positive vs. negative)

0.729

0.306–1.733

0.474

 

Adjuvant chemotherapy (received or not)

1.545

0.623–3.833

0.348

 

Adjuvant endocrine therapy (received or not)

1.820

0.766–4.324

0.175

  1. BM1 drawn prior to surgery, BM2 drawn three weeks after surgery, BM3 drawn six months after surgery;BM bone marrow; DTC disseminated tumor cell; ER Estrogen receptor; PgR Progesterone receptor; BM2/3 BM2 and/or BM3.
  2. *only patients with this sample available were included in the analysis.